NUVL Reports $1.2B Revenue, $0.08 EPS, NDA Submitted for Neladalkib, Zidesamtinib PDUFA Sep 18 2026, Label Expansion Planned H2 2026
Nuvalent, Inc. Class A Common Stock · PHARMACEUTICAL PREPARATIONS · Now $93.01
+2.8% in 1d after detection
Post-detection moves
1h
—
1d
+2.8%
3d
+0.1%
7d
-2.4%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS